Inactive Instrument

Press Releases Biostar Pharmaceuticals Inc Nasdaq

Equities

End-of-day quote Nasdaq Other stock markets
- ^USD	-

2023	Biostar Pharmaceuticals, Inc. Announces FDA Approval of Utidelone Injectable Phase 2/3 Multi-National Clinical Trial for Non-Small Cell Lung Cancer	CI
2023	Biostar Pharma, Inc. Announces First Patient Enrolled for Phase 1 Study of Utidelone Capsule	CI

No results for this search